{"id":"cal-101","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Diarrhea"},{"rate":"30-40%","effect":"Nausea"},{"rate":"20-30%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109562","moleculeType":"Unknown"},"_fixedAt":"2026-03-30T13:11:05.286054","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PI3K, CAL-101 disrupts the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. This leads to the induction of apoptosis in cancer cells.","oneSentence":"CAL-101 is a selective, irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:25.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"}]},"_fixedFields":["sideEffects","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT07139873","phase":"PHASE3","title":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","status":"RECRUITING","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","startDate":"2025-09-08","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":250},{"nctId":"NCT07218341","phase":"PHASE4","title":"A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-03","conditions":"Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic","enrollment":150},{"nctId":"NCT06846671","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-04-10","conditions":"CLL, Chronic Lymphocytic Leukemia","enrollment":250},{"nctId":"NCT02135133","phase":"PHASE2","title":"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":27},{"nctId":"NCT06736990","phase":"PHASE2","title":"A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Calluna Pharma AS","startDate":"2025-06-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":150},{"nctId":"NCT02970318","phase":"PHASE3","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-02-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":310},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT02787369","phase":"PHASE1","title":"ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-05","conditions":"Recurrent Chronic Lymphoid Leukemia","enrollment":3},{"nctId":"NCT03133221","phase":"PHASE2","title":"1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-10-23","conditions":"Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma","enrollment":17},{"nctId":"NCT02457598","phase":"PHASE1","title":"Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-06-16","conditions":"B-cell Malignancies","enrollment":203},{"nctId":"NCT04666038","phase":"PHASE3","title":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-03-09","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":238},{"nctId":"NCT03890289","phase":"PHASE2","title":"Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2019-10-18","conditions":"Follicular Lymphoma","enrollment":5},{"nctId":"NCT02445131","phase":"PHASE2","title":"Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2015-05-28","conditions":"Chronic Lymphocytic Leucemia","enrollment":48},{"nctId":"NCT06205290","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-16","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":""},{"nctId":"NCT03151057","phase":"PHASE1","title":"Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-07-31","conditions":"B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia, Follicular Lymphoma","enrollment":16},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT03257722","phase":"PHASE1, PHASE2","title":"Pembrolizumab + Idelalisib for Lung Cancer Study","status":"TERMINATED","sponsor":"Asha Nayak","startDate":"2017-09-26","conditions":"Non Small Cell Lung Cancer, Metastasis, Recurrence","enrollment":4},{"nctId":"NCT02332980","phase":"PHASE2","title":"Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-02-19","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","enrollment":65},{"nctId":"NCT04699461","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2021-11-04","conditions":"Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":6},{"nctId":"NCT02962401","phase":"PHASE2","title":"Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2017-03-07","conditions":"Waldenstrom Macroglobulinemia","enrollment":50},{"nctId":"NCT02536300","phase":"PHASE3","title":"Dose Optimization Study of Idelalisib in Follicular Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-01-14","conditions":"Follicular Lymphoma","enrollment":96},{"nctId":"NCT05725200","phase":"PHASE2","title":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2022-09-27","conditions":"Metastatic Colorectal Cancer","enrollment":40},{"nctId":"NCT02141282","phase":"PHASE2","title":"A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-10","conditions":"Chronic Lymphocytic Leukemia","enrollment":127},{"nctId":"NCT03545035","phase":"","title":"Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2019-02-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":104},{"nctId":"NCT02968563","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-12-13","conditions":"Chronic Lymphocytic Leukemia","enrollment":35},{"nctId":"NCT02639910","phase":"PHASE2","title":"Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi","status":"COMPLETED","sponsor":"MorphoSys AG","startDate":"2016-11","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":24},{"nctId":"NCT03568929","phase":"","title":"Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-05-25","conditions":"Follicular Non-Hodgkin's Lymphoma Refractory","enrollment":257},{"nctId":"NCT03639324","phase":"PHASE1","title":"Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2020-10-02","conditions":"Chronic Lymphocytic Leukemia, CLL, Relapsed CLL","enrollment":""},{"nctId":"NCT01620216","phase":"PHASE2","title":"Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2012-05-11","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia","enrollment":12},{"nctId":"NCT03576443","phase":"PHASE2","title":"Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Nordic Lymphoma Group","startDate":"2017-07-07","conditions":"Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT03742323","phase":"PHASE1, PHASE2","title":"REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"PETHEMA Foundation","startDate":"2018-07-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":6},{"nctId":"NCT02928510","phase":"","title":"Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2016-02-01","conditions":"Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma, Digestive System Signs and Symptoms","enrollment":1},{"nctId":"NCT01644253","phase":"PHASE1","title":"Phase 1b Safety and Efficacy Study of TRU-016","status":"TERMINATED","sponsor":"Aptevo Therapeutics","startDate":"2012-09","conditions":"Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma","enrollment":87},{"nctId":"NCT02468557","phase":"PHASE1","title":"Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-07-30","conditions":"Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma","enrollment":16},{"nctId":"NCT02242045","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-10-01","conditions":"Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":6},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT02824159","phase":"","title":"Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2016-04","conditions":"Hematological Malignancies","enrollment":121},{"nctId":"NCT02538614","phase":"PHASE1","title":"Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-12-29","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":2},{"nctId":"NCT02436135","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-06-05","conditions":"Myelofibrosis","enrollment":10},{"nctId":"NCT01796470","phase":"PHASE2","title":"Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-06-20","conditions":"Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma","enrollment":66},{"nctId":"NCT02779283","phase":"PHASE1","title":"Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2016-01-13","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT04379167","phase":"PHASE2","title":"A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma","status":"UNKNOWN","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2020-12-30","conditions":"Follicular Lymphoma","enrollment":140},{"nctId":"NCT01569295","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-06-15","conditions":"Chronic Lymphocytic Leukemia","enrollment":416},{"nctId":"NCT02739360","phase":"PHASE4","title":"Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-05-04","conditions":"Lymphoid Malignancies","enrollment":3},{"nctId":"NCT02603445","phase":"PHASE1","title":"Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-16","conditions":"Follicular Lymphoma, Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT03701438","phase":"","title":"Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2018-10-23","conditions":"B-cell Malignancies","enrollment":2},{"nctId":"NCT01090414","phase":"PHASE1, PHASE2","title":"An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2010-03-22","conditions":"Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin","enrollment":202},{"nctId":"NCT01539291","phase":"PHASE3","title":"Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2012-10-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":161},{"nctId":"NCT01659021","phase":"PHASE3","title":"Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2012-12-04","conditions":"Chronic Lymphocytic Leukemia","enrollment":261},{"nctId":"NCT04049929","phase":"PHASE1","title":"A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2019-08","conditions":"Advanced Solid Tumor","enrollment":50},{"nctId":"NCT01282424","phase":"PHASE2","title":"Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-03-18","conditions":"Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma","enrollment":125},{"nctId":"NCT02258529","phase":"PHASE2","title":"Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-09-14","conditions":"Follicular Lymphoma, Small Lymphocytic Lymphoma","enrollment":10},{"nctId":"NCT01539512","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-04","conditions":"Chronic Lymphocytic Leukemia","enrollment":220},{"nctId":"NCT02993536","phase":"","title":"Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab","status":"WITHDRAWN","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2015-11","conditions":"Chronic Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT03582098","phase":"","title":"Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-09-12","conditions":"Chronic Lymphocytic Leukaemia","enrollment":112},{"nctId":"NCT03349346","phase":"PHASE1","title":"Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2019-06","conditions":"Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma","enrollment":""},{"nctId":"NCT03757000","phase":"PHASE1","title":"A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies","status":"UNKNOWN","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2017-12-25","conditions":"B-cell Lymphoma Recurrent, B-cell Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT02044822","phase":"PHASE2","title":"Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-08-06","conditions":"B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion","enrollment":102},{"nctId":"NCT01393106","phase":"PHASE2","title":"Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT01980888","phase":"PHASE3","title":"Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-02-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":311},{"nctId":"NCT01306643","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-02","conditions":"Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma","enrollment":18},{"nctId":"NCT01980875","phase":"PHASE3","title":"Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-04-21","conditions":"Chronic Lymphocytic Leukemia","enrollment":57},{"nctId":"NCT01203930","phase":"PHASE2","title":"A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":105},{"nctId":"NCT01732926","phase":"PHASE3","title":"Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-01-02","conditions":"Indolent Non-Hodgkin's Lymphomas","enrollment":475},{"nctId":"NCT01732913","phase":"PHASE3","title":"Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-01-16","conditions":"Indolent Non-Hodgkin's Lymphomas","enrollment":295},{"nctId":"NCT00836914","phase":"PHASE1","title":"Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-02","conditions":"Allergic Rhinitis","enrollment":41},{"nctId":"NCT03469895","phase":"","title":"Autoimmune Cytopenia and BcR Inhibitors","status":"UNKNOWN","sponsor":"Institut Paoli-Calmettes","startDate":"2017-07-21","conditions":"Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia","enrollment":40},{"nctId":"NCT01838434","phase":"PHASE1","title":"Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-07","conditions":"Relapsed/Refractory Mantle Cell Lymphoma","enrollment":106},{"nctId":"NCT01644799","phase":"PHASE1","title":"Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-07","conditions":"Recurrent Follicular Lymphoma","enrollment":8},{"nctId":"NCT02662296","phase":"PHASE2","title":"Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-03","conditions":"Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT02590588","phase":"PHASE2","title":"Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis","status":"TERMINATED","sponsor":"John Mark Sloan","startDate":"2016-01","conditions":"Amyloidosis","enrollment":1},{"nctId":"NCT02439138","phase":"PHASE2","title":"Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-10","conditions":"Waldenstrom's Macroglobulinemia","enrollment":5},{"nctId":"NCT02136511","phase":"","title":"Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia","status":"APPROVED_FOR_MARKETING","sponsor":"Gilead Sciences","startDate":"","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":""},{"nctId":"NCT01659047","phase":"PHASE2","title":"A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2012-08","conditions":"Chronic Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT00710528","phase":"PHASE1","title":"Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-06","conditions":"Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML)","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":92,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Idelalisib","GS-1101"],"phase":"phase_2","status":"active","brandName":"CAL-101","genericName":"CAL-101","companyName":"German CLL Study Group","companyId":"german-cll-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAL-101 is a selective, irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K). Used for Chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}